Cloud robotics is an emerging field of robotics rooted in cloud computing, cloud storage, and other Internet technologies centered on the benefits of converged infrastructure and shared services.
Cloud robotics is an emerging field of robotics rooted in cloud computing, cloud storage, and other Internet technologies centered on the benefits of converged infrastructure and shared services. Connecting robots to the cloud increase computational power, storage, and communications. Cloud robots communicate with each other and thus operations are carried out easily.
The Google Cloud Robotics Platform combines AI, robotics, and the cloud to enable the opening of an ecosystem of automation solutions that use cloud-connected collaborative robots. Along with AI and machine learning services, the robots will be able to efficiently carry out processes in highly dynamic environments in the manufacturing industry. Moreover, in the industry, the cloud is an ally for processing a large amount of data. For instance, Exscientia and Celgene, a biopharmaceutical company, announced a €19.64 million deal in 2019 to speed up the discovery of medications for cancer and autoimmune illnesses.
Get sample Research Copy at: https://www.theinsightpartners.com/sample/TIPMD00002342/
Pharmaceutical Robots Market: Competitive Landscape and Key Development
ABB Ltd., Kawasaki Heavy Industries, Ltd., Yaskawa Electric Corporation, Universal Robots A/S, Marchesini Group S.p.A, Denso Corporation, Fanuc Corporation, Espon India Pvt. Ltd., Shibuya Corporation, and Weiss GmbH are among the leading companies operating in the pharmaceutical robots market.
These companies are adopting inorganic and organic growth strategies to expand their global footprints and product portfolio to meet the rising demands for the pharmaceutical robots. In March 2021, Yaskawa Electric Corporation launched a new hybrid Yaskawa cobot-MOTOMAN HC10DTF for food and pharmaceutical industries. The MOTOMAN HC10DTF fulfils the stringent hygienic requirements of the food and pharmaceutical industry pursuant to ISO Class 5 or EG-GMP Class A.
Based on product, the pharmaceutical robots market is segmented into traditional robots and collaborative pharmaceutical robots. In 2020, the traditional robots segment held a larger share of the market. The market growth of this segment is attributed to the increase in the use of robots in dispensing, sorting, kit assembly, and light machine-tending as well as in more traditional applications associated with packaging and others.
The pharmaceutical robots market is projected to reach US$ 383.91 million by 2028 from US$ 159.23 million in 2021; it is expected to grow at a CAGR of 13.4% from 2021 to 2028.
Pharmaceutical industry requires efficient and precise precision in production of pharmaceutical drugs. Thus, using robots in pharmaceutical manufacturing improves quality and reduces cost and time. Robots are proving advantageous in filling, inspection, packaging, laboratories, and the manufacture of personalized medicine. A robotic system is a type of automation that has multiple axes of motion and can be programmed to perform any function.
The organization also helps in risk assessment, risk management, and risk communication. The OIE has deployed an Incident Coordination System to coordinate these activities. Moreover, the COVID-19 pandemic and consequent lockdown impositions have significantly impacted the livestock and poultry sectors in different countries in the world. The demand–supply gap is found to decrease gradually with the opening-up of market chains and additional steps taken by the local administrations in plugging the bottlenecks in delivery systems. It is further envisaged that the impact would continue to be long-standing and will have great bearing on the livelihood, employment, and overall economy of the sector. The pharmaceutical robots market is segmented on the bases of dosage, disease, technology, and region. The market, based on region, is segmented into North America, Europe, Asia Pacific, Middle East and Africa, and South and Central America.
For instance, Exscientia and Celgene, a biopharmaceutical company, announced a €19.64 million deal in 2019 to speed up the discovery of medications for cancer and autoimmune illnesses. In 2020, it also announced a collaboration with other firms to find possible COVID-19 medications. As a result, the company now has access to a package of molecules, including medications and other chemicals, that have been successfully tested in humans. The company intended to scan the list for any medications that could be able to combat the virus.
Place a Purchase Order to Buy a Complete Copy of this Report @ https://www.theinsightpartners.com/buy/TIPMD00002342/
About Us:
The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We are a specialist in Technology, Semiconductors, Healthcare, Manufacturing, Automotive and Defense.
Contact Us:
Call: +1-646-491-9876
Email: sales@theinsightpartners.com